ARCHIVES

NIH Reauthorization Compromise Between House and Senate Gives NCI Three Year Authorization Period

This article is from The Cancer Letter archive.

Vol. 11 No. 40 | October 18, 1985

Download PDF Visit The Full Archive

Related Articles

FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors

June 24, 2011

New P01 Guidelines Will Go Into Effect Feb. 1 Not Oct. 1

September 16, 1983

In Brief: Best Guess On NCI Director: Brown First Choice, Benacerraf Second; FDa On Saccharin

April 22, 1977

Additional DCE Contract Concepts

November 16, 1984

Battelle Wins Big Toxiology Contract

March 22, 1974

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014